Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2015

Open Access 01-12-2015 | Research article

Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach

Authors: Spyros A Papiris, Konstantinos Kagouridis, Likurgos Kolilekas, Andriana I Papaioannou, Aneza Roussou, Christina Triantafillidou, Katerina Baou, Katerina Malagari, Stylianos Argentos, Anastasia Kotanidou, Anna Karakatsani, Effrosyni D Manali

Published in: BMC Pulmonary Medicine | Issue 1/2015

Login to get access

Abstract

Background

Idiopathic pulmonary fibrosis acute exacerbation (IPF-AE) constitutes IPF’s most devastating event, representing the unexpected superimposition of diffuse alveolar damage of unknown etiology. Guidelines recommend high-dose steroids treatment despite unproven benefit. We hypothesized that previous immunosuppression and the administration of high-dose steroids adversely affect IPF-AE outcome.

Methods

We studied all consecutive patients hospitalized in our department for IPF deterioration from 2007 to June 2013. Our protocol consisted of immediate cessation of immunosuppression (if any), best supportive care, broad-spectrum antimicrobials and thorough evaluation to detect reversible causes of deterioration. Patients were followed-up for survival; post-discharge none received immunosuppression.

Results

Twenty-four out of 85 admissions (28 %) fulfilled IPF-AE criteria. IPF-AE were analyzed both as unique events and as unique patients. As unique events 50 % survived; 3 out of 12 (25 %) in the group previously treated with immunosuppression whereas nine out of 12 (75 %) in the group not receiving immunosuppression (p = 0.041). As unique patients 35.3 % survived; 3 out of 6 (50 %) in the never treated group whereas three out of 11 (27.3 %) in the group receiving immunosuppression (p = 0.685). The history of immunosuppression significantly and adversely influenced survival (p = 0.035). Survival was greater in the never treated group compared to the immunosuppressed patients (p = 0.022). Post-discharge, our IPF-AE survivors had an 83 % 1-year survival.

Conclusions

By applying the above mentioned protocol half of our patients survived. The history of immunosuppression before IPF-AE adversely influences survival. Avoiding steroids in IPF patients may favor the natural history of the disease even at the moment of its most devastating event.
Literature
1.
go back to reference Papiris SA, Manali ED, Kolilekas L, Kagouridis K, Triantafillidou C, Tsangaris I, et al. Clinical review: idiopathic pulmonary fibrosis acute exacerbations-unravelling Ariadne's thread. Crit Care. 2010;14:246.PubMedCentralCrossRefPubMed Papiris SA, Manali ED, Kolilekas L, Kagouridis K, Triantafillidou C, Tsangaris I, et al. Clinical review: idiopathic pulmonary fibrosis acute exacerbations-unravelling Ariadne's thread. Crit Care. 2010;14:246.PubMedCentralCrossRefPubMed
2.
go back to reference Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King Jr TE, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–43.PubMedCentralCrossRefPubMed Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King Jr TE, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–43.PubMedCentralCrossRefPubMed
3.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRefPubMed Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRefPubMed
4.
go back to reference American Thoracic Society (ATS), and the European Respiratory Society (ERS), American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med. 2000;161:646–64.CrossRef American Thoracic Society (ATS), and the European Respiratory Society (ERS), American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med. 2000;161:646–64.CrossRef
5.
go back to reference Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–77.CrossRef Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–77.CrossRef
6.
go back to reference Papiris SA, Manali ED, Kolilekas L, Triantafillidou C, Tsangaris I, Kagouridis K. Steroids in idiopathic pulmonary fibrosis acute exacerbation: defenders or killers? Am J Respir Crit Care Med. 2012;185:587–8.CrossRefPubMed Papiris SA, Manali ED, Kolilekas L, Triantafillidou C, Tsangaris I, Kagouridis K. Steroids in idiopathic pulmonary fibrosis acute exacerbation: defenders or killers? Am J Respir Crit Care Med. 2012;185:587–8.CrossRefPubMed
7.
go back to reference Papiris S, Kagouridis K, Kolilekas L, Roussou A, Triantafillidou C, Baou K et al. Survival in IPF acute exacerbations: the non-steroid approach. ERS Congress. 2013;463. Papiris S, Kagouridis K, Kolilekas L, Roussou A, Triantafillidou C, Baou K et al. Survival in IPF acute exacerbations: the non-steroid approach. ERS Congress. 2013;463.
8.
go back to reference Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103:1808–12.CrossRefPubMed Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103:1808–12.CrossRefPubMed
9.
go back to reference Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005;128:3310–5.CrossRefPubMed Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005;128:3310–5.CrossRefPubMed
10.
go back to reference Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J. 2004;11:117–22.PubMed Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J. 2004;11:117–22.PubMed
11.
12.
go back to reference Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:356–63.CrossRefPubMed Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:356–63.CrossRefPubMed
13.
go back to reference Inase N, Sawada M, Ohtani Y, Miyake S, Isogai S, Sakashita H, et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med. 2003;42:565–70.CrossRefPubMed Inase N, Sawada M, Ohtani Y, Miyake S, Isogai S, Sakashita H, et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med. 2003;42:565–70.CrossRefPubMed
14.
go back to reference Sakamoto S, Homma S, Miyamoto A, Kurosaki A, Fujii T, Yoshimura K. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49:109–15.CrossRefPubMed Sakamoto S, Homma S, Miyamoto A, Kurosaki A, Fujii T, Yoshimura K. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49:109–15.CrossRefPubMed
15.
go back to reference Okamoto T, Ichiyasu H, Ichikado K, Muranaka H, Sato K, Okamoto S, et al. Clinical analysis of the acute exacerbation in patients with idiopathic pulmonary fibrosis. Nihon Kokyuki Gakkai Zasshi. 2006;44:359–67.PubMed Okamoto T, Ichiyasu H, Ichikado K, Muranaka H, Sato K, Okamoto S, et al. Clinical analysis of the acute exacerbation in patients with idiopathic pulmonary fibrosis. Nihon Kokyuki Gakkai Zasshi. 2006;44:359–67.PubMed
16.
go back to reference Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T, et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med. 2006;100:1753–9.CrossRefPubMed Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T, et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med. 2006;100:1753–9.CrossRefPubMed
17.
go back to reference Yokoyama T, Kondoh Y, Taniguchi H, Kataoka K, Kato K, Nishiyama O, et al. Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49:1509–14.CrossRefPubMed Yokoyama T, Kondoh Y, Taniguchi H, Kataoka K, Kato K, Nishiyama O, et al. Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49:1509–14.CrossRefPubMed
18.
go back to reference Morawiec E, Tillie-Leblond I, Pansini V, Salleron J, Remy-Jardin M, Wallaert B. Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses. Eur Respir J. 2011;38:1487–9.CrossRefPubMed Morawiec E, Tillie-Leblond I, Pansini V, Salleron J, Remy-Jardin M, Wallaert B. Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses. Eur Respir J. 2011;38:1487–9.CrossRefPubMed
19.
go back to reference Simon-Blancal V, Freynet O, Nunes H, Bouvry D, Naggara N, Brillet PY, et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration. 2012;83:28–35.CrossRefPubMed Simon-Blancal V, Freynet O, Nunes H, Bouvry D, Naggara N, Brillet PY, et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration. 2012;83:28–35.CrossRefPubMed
20.
go back to reference Antoniou KM, Wells AU. Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Respiration. 2013;18:265–74.CrossRef Antoniou KM, Wells AU. Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Respiration. 2013;18:265–74.CrossRef
21.
go back to reference Papiris SA, Kagouridis K, Kolilekas L, Bouros D, Manali ED. Idiopathic Pulmonary Fibrosis Acute Exacerbations: Where Are We Now? Expert Rev Respir Med. 2014;8(3):271–3.CrossRefPubMed Papiris SA, Kagouridis K, Kolilekas L, Bouros D, Manali ED. Idiopathic Pulmonary Fibrosis Acute Exacerbations: Where Are We Now? Expert Rev Respir Med. 2014;8(3):271–3.CrossRefPubMed
22.
23.
go back to reference Richter AG, Stockley RA, Harper L, Thickett DR. Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis. Thorax. 2009;64:692–7.CrossRefPubMed Richter AG, Stockley RA, Harper L, Thickett DR. Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis. Thorax. 2009;64:692–7.CrossRefPubMed
24.
go back to reference Papiris SA, Maniati M, Kagouridis K, Kolilekas L, Triantafillidou C, Papadaki G, et al. Idiopathic Pulmonary Fibrosis Acute Exacerbations: Time to “turn the screw”. TREATMENT STRATEGIES CAMBRIDGE RESEARCH CENTRE Papiris SA, Maniati M, Kagouridis K, Kolilekas L, Triantafillidou C, Papadaki G, et al. Idiopathic Pulmonary Fibrosis Acute Exacerbations: Time to “turn the screw”. TREATMENT STRATEGIES CAMBRIDGE RESEARCH CENTRE
25.
go back to reference The Human Microbiome Project Consortium. Structure, Function and Diversity of the Healthy Human Microbiome”. Nature. 2013;486:207–14. The Human Microbiome Project Consortium. Structure, Function and Diversity of the Healthy Human Microbiome”. Nature. 2013;486:207–14.
26.
go back to reference Han MK, Zhou Y, Murray S, for the COMET Investigators, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2:548–56.PubMedCentralCrossRefPubMed Han MK, Zhou Y, Murray S, for the COMET Investigators, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2:548–56.PubMedCentralCrossRefPubMed
27.
go back to reference Shimizu Y, Sunaga N, Dobashi K, Fueki M, Fueki N, Makino S, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009;9:47.PubMedCentralCrossRefPubMed Shimizu Y, Sunaga N, Dobashi K, Fueki M, Fueki N, Makino S, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009;9:47.PubMedCentralCrossRefPubMed
28.
go back to reference Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190:906–13.PubMedCentralCrossRefPubMed Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190:906–13.PubMedCentralCrossRefPubMed
29.
go back to reference Oda K, Ishimoto H, Yamada S, Kushima H, Ishii H, Imanaga T, et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2014;15:109 [Epub ahead of print].PubMedCentralCrossRefPubMed Oda K, Ishimoto H, Yamada S, Kushima H, Ishii H, Imanaga T, et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2014;15:109 [Epub ahead of print].PubMedCentralCrossRefPubMed
30.
go back to reference Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:1698–702.PubMedCentralCrossRefPubMed Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:1698–702.PubMedCentralCrossRefPubMed
31.
go back to reference Johannson K, Collard HR. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal. Curr Respir Care Rep. 2013;2(4). doi: 10.1007/s13665-013-0065-x. Johannson K, Collard HR. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal. Curr Respir Care Rep. 2013;2(4). doi: 10.1007/s13665-013-0065-x.
Metadata
Title
Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach
Authors
Spyros A Papiris
Konstantinos Kagouridis
Likurgos Kolilekas
Andriana I Papaioannou
Aneza Roussou
Christina Triantafillidou
Katerina Baou
Katerina Malagari
Stylianos Argentos
Anastasia Kotanidou
Anna Karakatsani
Effrosyni D Manali
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2015
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-015-0146-4

Other articles of this Issue 1/2015

BMC Pulmonary Medicine 1/2015 Go to the issue